Refsum
disease is a genetic disorder which is inherited as an autosomal recessive
trait. The condition is characterized by progressive loss of vision (retinitis
pigmentosa), failure of muscle coordination (ataxia), degenerative nerve
disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The
accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the
main cause of refsum disease. This occurs due to malfunction of the enzyme producing
gene that metabolizes phytanic acid. According to the U.S. National Library of
Medicine, more than 90 % cases of refsum disease result from the mutations in
PHYH gene, and the remaining cases are caused by mutations in a gene PEX7 gene.
Notably,
increasing awareness among people is the key factor driving the refsum disease
market. According to the National Organization of Rare Diseases, the age of
onset of refsum disorder varies greatly. The disease can occur at any time from
early childhood to nearly 50 years of age, but in most cases will have appeared
by age 20. Males and females are equally affected in numbers.
Various
other push factors such as increasing awareness among people, increasing
government assistance, improving regulatory framework, and rising funding and
reimbursement continuously contributing to the growth of the global refsum
disease market.
Despite
these drivers, there are some issues associated with refsum disease market.
Some of the challenges in research and development, and poor healthcare system
in low and middle-income countries may hinder the growth of the market to some
extent.
It
is estimated that the refsum disease market is expected to grow at a CAGR 5.4%
during the forecast period of 2019-2023.
Key
Players
·
Fresenius
Kabi,
·
B.
Braun Medical Inc.,
·
Medline
Industries, Inc.,
·
Illumina,
Inc.,
·
Igenomix,
·
Ceuta
Healthcare Limited,
·
Cochlear
Ltd.,
·
Cook,
·
Sonova,
·
William
Demant Holding A/S,
·
Nurotron
Biotechnology Co. Ltd.,
·
Agilent
Technologies,
·
Bio-Rad
Laboratories, Inc.,
·
Sequenom.
Segmentation
The
global refsum disease market is segmented on the basis of type, diagnosis,
treatment, and end-user.
On
the basis of the type, the market is segmented into adult refsum disease, and
others. The adult refsum disease is further segmented into adult refsum disease
1, and adult refsum disease 2.
On
the basis of the treatment, the market is classified as medical care, and
surgical care. The medical care is further segmented into diet, plasmapheresis,
and medication. The sub-segments of medication include keratolytics, and
others.
On
the basis of the diagnosis, the market is classified into physical examination,
molecular genetic testing, prenatal screening tests, preimplantation genetic
diagnosis, enzyme analysis, anosmia testing, and others. The molecular genetic
testing is further segmented into genotyping, sequencing of gene, amplification
or hybridization method, methylation-specific techniques, and others. The
prenatal screening tests are further segmented into ultrasound, blood tests,
chorionic villus sampling (CVS), amniocentesis, and others.
On
the basis of the end-user, the market is segmented into hospital, clinics,
diagnostic centers, research & academic institutes, and others.
Browse
Complete 85 Pages Premium Research Report Enabled with Respective Tables and
Figures @ https://www.marketresearchfuture.com/reports/refsum-disease-market-5176
Regional
Analysis
The
Asia Pacific is the fastest growing refsum disease market owing to a huge
patient pool and developing healthcare technology. Healthcare expenditure is
also improving in various Asia Pacific countries. According to the Australian
Institute of Health and Welfare in the years 2015-2016, the total health
expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of
2014-2015.
The
Americas dominate the refsum disease market owing to the rising awareness among
people and high healthcare expenditure. According to the Centers for Disease Control
and Prevention in 2015, the total health expenditure in the United States was
reported to be USD 3.2 trillion and hospital care accounted for a share of
32.3%.
Europe
holds the second position in the refsum disease market. It is expected that the
support provided by the government bodies for research & development and
improvement in reimbursement policies in healthcare is likely to drive the
market of the European region.
The
Middle East & Africa holds the lowest market due to lack of technical knowledge
and poor medical facilities.
About
US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact
Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
No comments:
Post a Comment